LPL and Hypercholesterolemia: P-407 has been known to cause significant dose-dependent hypercholesterolemia and hypertriglyceridemia in rats via several mechanisms (e.g., inhibition of lipoprotein lipase, indirect stimulation of HMG-CoA (3-hydroxy-3-methylglutarylCo-A) reductase, and promotion of concentration of hepatic cholesterol content) [14].